Novartis resumes production of radioligand therapy medicines

1 minute read

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann

Register now for FREE unlimited access to Reuters.com

ZURICH, June 30 (Reuters) - Novartis (NOVN.S) said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month. read more

"The company has remediated the issues that led to the temporary, voluntary suspension of production in May," the Swiss drugmaker said in a statement, adding these issues did not affect patient safety.

Register now for FREE unlimited access to Reuters.com
Reporting by Silke Koltrowitz Editing by Paul Carrel

Our Standards: The Thomson Reuters Trust Principles.